Key statistics
On Friday, Verrica Pharmaceuticals Inc (1NE:STU) closed at 1.29, 30.06% above the 52 week low of 0.988 set on Oct 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.29 |
---|---|
High | 1.33 |
Low | 1.29 |
Bid | 1.18 |
Offer | 1.22 |
Previous close | 0.988 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.67m |
Free float | 20.95m |
P/E (TTM) | -- |
Market cap | 55.90m USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of Oct 04 2024.
More ▼
Announcements
- Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
- Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
More ▼